Does perioperative chemotherapy improve outcomes in PDAC? Evidence is not yet conclusive
Trials provide insights into perioperative and adjuvant chemotherapy for resectable pancreatic cancer
KRAS G12C inhibition shows potential for the improved management of advanced CRC
Good response rate and disease control with adagrasib and sotorasib in combination therapy shown in early-stage trials
Novel immunotherapy-containing strategies look promising in microsatellite stable mCRC
Immune chemo-sensitisation results show potential for this approach in the treatment of advanced CRC, but greater understanding of response characteristics is required in future clinical trials
Two studies explore molecular divergence in gastric cancer
Genomic landscaping suggests molecular divergence between cancer subtypes and across disease stages, but molecular similarities between White and Asian populations
Updated results from the BEACON trial show unprecedented overall survival in the second-line treatment of CRC
Triplet targeted combination therapy appears to induce potent BRAF kinase signalling inhibition in patients with BRAFV600E-mutated metastatic colorectal cancer
ClarIDHy trial reports a small improvement in progression-free survival
Targeting isocitrate dehydrogenase 1 mutations in cholangiocarcinoma is a promising strategy
Targeting HER2 amplifications in metastatic colorectal cancer: searching for the most active combination therapy?
Mixed results from the the HERACLES-B, TRIUMPH and MOUNTAINEER trials
Clinical benefits from antibody–drug conjugates are reported for bladder cancer
At ESMO 2019, early clinical data from two studies show the promise of this new generation of treatments although not yet practice-changing
Precision medicine bursts onto the biliary tract cancer scene
The management of biliary tract cancers, especially cholangiocarcinoma, is rapidly changing with emerging new precision medicine strategies